Newborn Screening for SMA and SCID Market Size, Trends, Share, Growth, and Opportunity Forecast, 2024 - 2031 Global Industry Analysis By Product Type (Instruments, Equipment, Kits, and Software), By Technology (Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Immunoassays, Tandem Mass Spectrometry (TMS), and Others), By Test Type (Genetic Testing, Immunological Testing, Biochemical Testing, and Others), By End-User (Hospitals & Clinics, Research Institutions, and Diagnostic Laboratories) and By Geography (North America, Europe, Asia Pacific, South America, and Middle East & Africa)

The Global Newborn Screening for SMA and SCID Market was valued at USD 140.2 Million in 2023 and is anticipated to reach a value of USD 312.8 Million by 2031 expanding at a CAGR of 10.6% between 2024 and 2031.

Newborn screening for Spinal Muscular Atrophy (SMA) and Severe Combined Immunodeficiency (SCID) uses a series of tests for diagnosis and treatment serious genetic disorders. Newborn screening for SMA and SCID is a vital perspective for prevention of permanent disabilities or mortality of a new born child. SCID is a congenital genetic disorder     that causes life-threatening problems by suppressing the immune system. SCID is caused by mutations in various genes involved in the development and function of immune cells that fi­ght infection. SMA is a genetic neuromuscular disorder that affects the nerve cells responsible for muscle movement. SMA is defined by the loss of motor neurons in the spinal cord and brainstem. Newborn screening for SMA process uses the same dried blood spots already collected for screening of other disorders. Newborns missing the presence of the SMN1 gene are at high risk for SMA. The market is growing rapidly due to factors such as growing prevalence of newborn disorders, increasing accessibility of effective treatments, supportive government initiatives, and focus on early detection and treatment.

Newborn Screening for SMA and SCID Market Major Driving Forces

Growing Prevalence of Newborn Disorders: The rising prevalence of newborn diseases in recent years is driving the growth of the market. The increasing incidences of these disorders prompting providers to raise awareness and support the demand for advanced screening solutions.

Increasing Accessibility of Effective Treatments: The increasing accessibility of effective treatments across different regions is a significant factor influencing the growth of newborn screening for SMA and SCID market. The development of effective treatments for SMA, such as gene therapy, and advancements in bone marrow transplant for SCID have made early diagnosis more crucial.  

Supportive Government Initiatives: The supportive government initiatives promoting universal newborn screening programs have bolstered market expansion. Governments of different countries are increasingly allocating funds for newborn screening programs to reduce long-term healthcare costs for children and their parents.

Focus on Early Detection and Treatment: The growing emphasis on early detection for the effective treatment for preventing serious complications is another factor driving the demand for newborn screening for SMA and SCID. Early detection through newborn screening can significantly improve outcomes by enabling timely and effective treatment.

Newborn Screening for SMA and SCID Market Key Opportunities

Technological Innovation: Ongoing advancements in newborn screening technology is expected to drive innovation in the industry. These advancements in technology have led to the development of more accurate and cost-effective screening methods. Integrating next-generation sequencing (NGS) for more comprehensive, accurate screening, and broader genetic analysis may improve access and early detection rates.

Growing Focus on Preventive Healthcare: The growing emphasis on preventive healthcare have increased the demand for early detection solutions, which is propelling the market growth. Increasing focus on preventive healthcare and early disease detection is boosting demand for newborn screening for SMA and SCID.

Implementation of Screening Programs: Governments of different countries are increasingly allocating funds for newborn screening programs. These programs are aim at educating parents and healthcare providers about SMA, SCID, and the importance of newborn screening is crucial to increase consent rates and early detection.  

Newborn Screening for SMA and SCID Market Key Trends

·         The increasing introduction of SMA and SCID screening in newborn screening programs globally is a major trend in the market

·         Advancements in technology have led to the development of more accurate and cost-effective screening techniques

·         The increasing accessibility of effective treatment make early diagnosis even more crucial is another significant trend shaping the market growth

·         The supportive government initiatives promoting universal newborn screening programs have bolstered market expansion

·         The rising prevalence of genetic disorders is a major factor influencing the demand for newborn screening for SMA and SCID distribution

·         The growing emphasis on preventive healthcare have fueled the demand for early detection solutions

·         Integration of NGS (Next-Generation Sequencing) is becoming more popular, allowing for more comprehensive and accurate screening

Region-wise Market Insights

North America accounted for the largest market share at 41.2% in 2023 whereas, Asia Pacific is expected to register the fastest growth, expanding at a CAGR of 11.0% between 2024 and 2031.

North America region dominates the global newborn screening for SMA and SCID market with largest market share. This dominance is driven by advanced healthcare infrastructure, availability of newborn screening programs, favorable reimbursement policies, and strong presence of market players in the region. Additionally, in North America, the growing focus on technological innovation, government initiatives, high awareness, and the availability of advanced treatments also contributed to the market growth. In Europe, the growth is attributed to the Increasing awareness of newborn screening programs, well-established healthcare systems, and embrace of cutting-edge technology. In Asia-Pacific, the market is characterized by increasing birth rates, developing cost-effective screening techniques, public awareness regarding early diagnosis, and government initiatives which has created an increasing demand for newborn screening for SMA and SCID. The Middle East and Africa has been witnessing a growing demand for newborn screening for SMA and SCIDs with robust healthcare systems whereas, in South America, the market is influenced by economic factors, with developing healthcare infrastructure, and government support.

Market Competition Landscape

The global newborn screening for SMA and SCID market is highly consolidated with the intense competition among a large number of manufacturers operating globally as well as regionally. Key players in the newborn screening for SMA and SCID market are adopting various business growth strategies aimed at gaining a competitive edge. These strategies include product innovation, design differentiation, and the incorporation of innovative technologies to meet evolving consumer preferences. Established brands leverage their reputation for quality and reliability to maintain market share, while newer entrants focus on disruptive innovations and unique selling propositions.

These key players are driving the advancement in technology and adoption of advanced newborn screening for SMA and SCID through innovative technologies, comprehensive screening solutions. These players also focusing on strategic partnerships and commercialization for market expansion.

Key players in the global newborn screening for SMA and SCID market implement various organic and inorganic strategies to strengthen and improve their market positioning. Prominent players in the market include:

·         PerkinElmer

·         Natus Medical

·         ImmunoIVD AB

·         Thermo Fisher Scientific Inc.

·         Labsystems Diagnostics Oy

·         Bio-Rad Laboratories

·         Danaher Corporation

·         Medtronic

·         Chromsystems Instruments & Chemicals GmbH

·         Baebies, Inc.

·         Agilent Technologies, Inc.

·         Illumina, Inc.

·         F. Hoffmann-La Roche Ltd.

·         Seegene Inc.